TITLE

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review

AUTHOR(S)
Kandula, Mahesh; Kumar Ch, Kalyan; Raju YS, Ammi
PUB. DATE
August 2013
SOURCE
World Journal of Oncology;2013, Vol. 4 Issue 3, p137
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tripple negative breast cancer (TNBC) accounts for approximately 15% of breast cancers. It is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER-2 Over expression. Expression of ER, PR and HER-2 plays an important role in therapeutic assessment of patients with breast cancer. TNBC is not one disease, but a family of diseases, some of which are highly aggressive with limited treatment options. Triple-negative breast cancers Patients are not benefiting from currently available receptor- targeted systemic therapy. At present, there is no single agent that targets triple-negative breast cancer. However, researchers are presently investigating large number of potential therapies that may eventually improve outcomes in these patients. In this review article, we discussed about tripple negative breast cancer, also the role of BRCA gene mutations and targeted therapeutic options available to triple negative breast cancer patients.
ACCESSION #
89553030

 

Related Articles

  • Biology matters: the clinical impact of single-receptor discordance on breast cancer. Farolfi, A.; Ibrahim, T.; Scarpi, E.; Amadori, D. // Annals of Oncology;Mar2013, Vol. 24 Issue 3, p851 

    No abstract available.

  • The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. Qing Qu; Yu Zong; Xiao-chun Fei; Xiao-song Chen; Cheng Xu; Gu-yin Lou; Kun-wei Shen // World Journal of Surgical Oncology;2014, Vol. 12 Issue 1, p1 

    Background Receptor status discordance, such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status between primary breast cancer and metastatic lesions has been reported. The aim of this study was to evaluate the biopsy of clinically...

  • Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells. Nowsheen, Somaira; Cooper, Tiffiny; Stanley, Jennifer A.; Yang, Eddy S. // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Few therapeutic options exist for the highly aggressive triple negative breast cancers (TNBCs). In this study, we report that a contextual synthetic lethality can be achieved both in vitro and in vivo with combined EGFR and PARP inhibition with lapatinib and ABT-888, respectively. The mechanism...

  • Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Gullo, G.; Zuradelli, M.; Sclafani, F.; Santoro, A.; Crown, J. // Annals of Oncology;Aug2012, Vol. 23 Issue 8, p2204 

    No abstract available.

  • PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis. Paul, A; Gunewardena, S; Stecklein, S R; Saha, B; Parelkar, N; Danley, M; Rajendran, G; Home, P; Ray, S; Jokar, I; Vielhauer, G A; Jensen, R A; Tawfik, O; Paul, S // Cell Death & Differentiation;Sep2014, Vol. 21 Issue 9, p1469 

    Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2/neu), and the patients with TNBC are often diagnosed with higher rates of recurrence and metastasis....

  • Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Dekker, T. J. A.; Smit, V. T. H. B. M.; Hooijer, G. K. J.; Van de Vijver, M. J.; Mesker, W. E.; Tollenaar, R. A. E. M.; Nortier, J. W. R.; Kroep, J. R. // Annals of Oncology;Apr2013, Vol. 24 Issue 4, p931 

    Background Several studies have assessed the concordance of estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) status between core needle biopsy (CNB) and resection specimens, usually in small patient series and with discordant results. Patients and methods ER and HER2...

  • Triple-Negatif/Bazal Benzeri Meme Kanserinin Imm�nohistokimyasal �zellikleri. PALA, Emel Ebru; BAYOL, �mit; CUMURCU, S�heyla; KESKIN, Elif // Turkish Journal of Pathology;2012, Vol. 28 Issue 3, p238 

    Objective: Triple-negative-breast-cancer that accounts for 10-20% of all breast carcinomas is defined by the lack of estrogen receptor, progesterone receptor, HER2 expression, and agressive clinical behavior. Triple-negative-breast-cancer is categorized into basal like and other types. The...

  • Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer. Cubukcu, Erdem; Olmez, Omer Fatih; Kanat, Ozkan; Kabul, Selva; Canhoroz, Mustafa; Avci, Nilufer; Hartavi, Mustafa; Deligonul, Adem; Çubukçu, Sinem; Manavoglu, Osman // Contemporary Oncology / Wspolczesna Onkologia;2014, Vol. 18 Issue 1, p34 

    Introduction: Triple-negative breast cancers (TNBCs) - which lack the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) - have no established markers that can be used for prognostic stratification. As adiponectin has been...

  • Clinicopathological study of centrally necrotizing carcinoma of the breast. Yanling Zhang; Yurong Ou; Donghong Yu; Xiang Yong; Xiaoli Wang; Bo Zhu; Qiong Zhang; Lei Zhou; Zhaogen Cai; Zenong Cheng // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Centrally necrotizing carcinoma of the breast (CNC) represents a newly-identified subset of breast cancer. The clinical and pathological characteristics of this breast cancer subtype are not yet completely understood. Methods: We assessed the clinicopathological characteristics of 73...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics